# Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma

> **NCT05765084** · PHASE1,PHASE2 · RECRUITING · sponsor: **University Hospital, Antwerp** · enrollment: 15 (estimated)

## Conditions studied

- Malignant Pleural Mesothelioma

## Interventions

- **BIOLOGICAL:** Dendritic cell vaccination
- **DRUG:** Atezolizumab
- **DRUG:** Platinum/pemetrexed based chemotherapy

## Key facts

- **NCT ID:** NCT05765084
- **Lead sponsor:** University Hospital, Antwerp
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-24
- **Primary completion:** 2026-10
- **Final completion:** 2026-10
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2024-05-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05765084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05765084, "Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05765084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*